WebApr 15, 2024 · GlaxoSmithKline (GSK) and Sierra Oncology, a late-stage biopharmaceutical company focused on treatments of rare forms of cancer, announced on April 13, 2024 that they have entered into an agreement under which GSK will acquire Sierra Oncology. The acquisition is valued at $1.9 billion at $55 per share of common stock in cash. WebApr 14, 2024 · By Alex Philippidis. -. April 14, 2024. GlaxoSmithKline (GSK) signaled its intent to expand its oncology pipeline with its planned $1.9 billion acquisition of Sierra Oncology. Sierra’s investors ...
GSK agrees to buy Sierra Oncology for $1.9bn - Sharecast.com
WebApr 13, 2024 · GlaxoSmithKline has agreed to acquire Sierra Oncology for $1.9 billion in a bet that an experimental drug the small biotech developed is on the cusp of becoming a … WebOncology; Opportunity-driven; Technologies ... Trade marks are owned by or licensed to the GSK group of companies. GSK plc. Registered in England and Wales No. 3888792. … east midlands airport stay and fly
GSK Agrees To Acquire Sierra Oncology For $1.9 Bln Nasdaq
WebAs of April 2024 Sierra Oncology has a market cap of $1.34 Billion . This makes Sierra Oncology the world's 4259th most valuable company by market cap according to our data. The market capitalization, commonly called market cap, is the total market value of a publicly traded company's outstanding shares and is commonly used to measure how … WebJul 7, 2024 · Even as GSK moves closer to spinning out its consumer healthcare business, New GSK, the pharma business, continues to strengthen its own position. This week, the company completed its acquisition of California-based Sierra Oncology. In April, GSK plunked down $1.9 billion to acquire Sierra as a complementary oncology business. WebOncology; Opportunity-driven; Technologies ... Trade marks are owned by or licensed to the GSK group of companies. GSK plc. Registered in England and Wales No. 3888792. … culture of vail resorts